select trial semaglutide cardiovascular outcomes non-diabetic 2023 💡SELECT Trial💡 A breakthrough in Cardiology Field published its findings on 11th November 2023. It showed a significant reduction in the incidence of CV death, nonfatal MI or… Semaglutide Shows Secondary Cardiovascular Prevention

Yes, but ensure it stays cool using an insulated bag with ice packs

Change in body weight from baseline was dose-dependent, and at 1.2 mg was 7.5% at day 36 (one week after the final dose), consistent with or better than marketed and clinical-stage GLP-1 / GIP compounds

Vitamin C has antioxidant and skin-brightening effects on the skin that help reduce skin redness, and can help fade hyperpigmentation on the skin

DSIP ,

doi: 10.1080/09513590.2021.2014665 21 BanaszewskaBWrotyska-BarczyskaJSpaczynskiRZPawelczykLDulebaAJ

Upon binding to their respective receptors on pancreatic beta cells, GIP and GLP-1 enhance insulin secretion in a glucose-dependent manner